BKM120: Clinical Trials

32 trials of BKM120, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 7 terminated, 4 withdrawn, 2 unknown. 32 Phase 2, 5 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 232Completed 19, Terminated 7, Withdrawn 4, Unknown 2
Phase 15Completed 3, Terminated 2
Phase 31Completed 1

Follow BKM120: new trials by email Literature Review of BKM120 trials Research Report on BKM120

Trials (filtered) newest first · largest first

All 32 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer
BKM120 - Treatment for Metastatic or Locally Advanced Cervical Cancer
Phase 2WithdrawnNovartis Pharmaceuticals2015-11-012017-04-20
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Buparlisib, Sonidegib - Carcinoma, Basal Cell, Recurrent Skin Cancer
Phase 2TerminatedAnne Chang102015-02-012019-01-29
Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer
BKM120, Tamoxifen - Breast Cancer
Phase 2CompletedUniversity Hospital, Essen482014-12-012018-04-20
A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
BKM120 - Thymoma
Phase 2CompletedPatrick Joseph Loehrer Sr.142014-10-012022-04-11
Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer
paclitaxel, BKM120 - Breast Neoplasms
Phase 2WithdrawnWashington University School of Medicine2014-08-012014-12-08
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
LGX818, MEK162, LEE011 - Melanoma
Phase 2CompletedPfizer1582014-07-232024-03-05
STAR Cape+BKM120 MBC With Brain Met
BKM120, capecitabine, Trastuzumab - Brain Metastases, Breast Cancer
Phase 2CompletedUS Oncology Research102014-05-292022-02-07
BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers
BKM120 - Endometrial Cancer
Phase 2WithdrawnUniversity of Utah2014-05-012014-07-29
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
alpelisib, buparlisib, Placebo - Breast Cancer
Phase 2CompletedNovartis Pharmaceuticals3402014-03-112018-09-14
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
INC280, Buparlisib - c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals432014-01-092018-05-30
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
Buparlisib, Buparlisib matching Placebo, Paclitaxel - Head and Neck Squamous Cell Carcinoma
Phase 2TerminatedNovartis Pharmaceuticals1572013-10-012018-07-24
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
BKM120, Trastuzumab, Paclitaxel - HER2-positive Newly Diagnosed, Primary Breast Cancer
Phase 2CompletedNovartis Pharmaceuticals502013-09-032019-11-14
BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy
BKM120 - Esophageal Cancer
Phase 2TerminatedPrince of Songkla University52013-07-012021-10-11
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
PI3K inhibitor BKM120, cetuximab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase 1 / Phase 2CompletedUniversity of Chicago122013-05-012021-10-05
Neoadjuvant BKM120 in High-risk Prostate Cancer
BKM120 - High Risk Prostate Cancer
Phase 2TerminatedWon Kim112013-04-232021-01-13
A Multicenter Phase II Pilot Open Label
BKM120 - Thyroid Cancers
Phase 2UnknownHospices Civils de Lyon472013-04-012016-10-05
BKM120 for Patients With PI3K-activated Tumors
BKM120 - PI3K Pathway Activated Tumors
Phase 2CompletedNovartis Pharmaceuticals1462013-03-292018-10-19
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
Buparlisib - Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Phase 2CompletedNovartis Pharmaceuticals722013-02-282018-09-28
Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive
BKM120 - Head and Neck Neoplasms, Neoplasm Metastasis
Phase 2CompletedCentre Leon Berard582013-01-012019-06-24
P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.
BKM120, Panitumumab - Metastatic Colorectal Cancer
Phase 1 / Phase 2CompletedCanadian Cancer Trials Group222012-09-062023-08-04

Showing 20 of 32. Sign in to see all of them.

Conditions studied

Breast Neoplasms (10)  ·  Neoplasm Metastasis (7)  ·  Brain Neoplasms (4)  ·  Glioblastoma (3)  ·  Colorectal Neoplasms (2)  ·  Endometrial Neoplasms (2)  ·  Head and Neck Neoplasms (2)  ·  Prostatic Neoplasms (2)  ·  Recurrence (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Triple Negative Breast Neoplasms (2)  ·  Basal Cell Nevus Syndrome (1)  ·  Carcinoma, Basal Cell (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Squamous Cell (1)

Sponsors

Novartis Pharmaceuticals (11)  ·  ARCAGY/ GINECO GROUP (1)  ·  Andrew J. Armstrong, MD (1)  ·  Anne Chang (1)  ·  Canadian Cancer Trials Group (1)  ·  Centre Leon Berard (1)  ·  Dana-Farber Cancer Institute (1)  ·  Hospices Civils de Lyon (1)  ·  L. Nicolas Gonzalez Castro, MD, PhD (1)  ·  Massachusetts General Hospital (1)  ·  Patrick Joseph Loehrer Sr. (1)  ·  Pfizer (1)  ·  Prince of Songkla University (1)  ·  SCRI Development Innovations, LLC (1)  ·  SOLTI Breast Cancer Research Group (1)

Countries

United States (21)  ·  Spain (11)  ·  Germany (10)  ·  France (9)  ·  Italy (8)  ·  Canada (7)  ·  Australia (6)  ·  Belgium (6)  ·  Brazil (5)  ·  Japan (5)  ·  Netherlands (5)  ·  United Kingdom (5)  ·  South Korea (4)  ·  Austria (3)  ·  Hong Kong (3)

Top investigators

Andrew Armstrong, MD, ScM (1)  ·  Anja Welt, MD (1)  ·  Anne Lynn Chang, MD (1)  ·  Arunee Dechaphunkul, MD (1)  ·  Byoung Chul Cho, M.D., Ph.D. (1)  ·  Derek Jonker (1)  ·  Eric Winer, MD (1)  ·  Foluso Ademuyiwa, M.D., M.P.H. (1)  ·  Isabelle Ray-Coquard, MD (1)  ·  Jeffrey A Engelman, MD, PhD (1)  ·  Jordi Rodon, MD (1)  ·  Jose Baselga, MD (1)  ·  Joyce A. O'Shaughnessy, MD (1)

Results publications

PMID 33138866, PMID 26098748, PMID 26766736, PMID 28131786, PMID 28923573, PMID 28971900, PMID 29175429, PMID 30105951, PMID 30715997, PMID 30723140, PMID 31506897, PMID 31776899, PMID 32963347, PMID 34376578, PMID 36330484, PMID 39808408, PMID 41914670

NIH funding

2009 (1), 2014 (1)